27929135|t|Early life vaccination: Generation of adult - quality memory CD8+ T cells in infant mice using non-replicating adenoviral vectors
27929135|a|Intracellular pathogens represent a serious threat during early life. Importantly, even though the immune system of newborns may be characterized as developmentally immature, with a propensity to develop Th2 immunity, significant CD8+ T-cell responses may still be elicited in the context of optimal priming. Replication deficient adenoviral vectors have been demonstrated to induce potent CD8+ T-cell response in mice, primates and humans. The aim of the present study was therefore to assess whether replication-deficient adenovectors could overcome the risk of overwhelming antigen stimulation during the first period of life and provide a pertinent alternative in infant vaccinology. To address this, infant mice were vaccinated with three different adenoviral vectors and the CD8+ T-cell response after early life vaccination was explored. We assessed the frequency, polyfunctionality and in vivo cytotoxicity of the elicited memory CD8+ T cells, as well as the potential of these cells to respond to secondary infections and confer protection. We further tested the impact of maternal immunity against our replication-deficient adenoviral vector during early life vaccination. Overall, our results indicate that memory CD8+ T cells induced by adenoviral vectors in infant mice are of good quality and match those elicited in the adult host.
27929135	0	5	Early	T079	C1279919
27929135	6	10	life	T078	C0376558
27929135	11	22	vaccination	T061	C0042196
27929135	24	34	Generation	T052	C3146294
27929135	38	43	adult	T008	C0596888
27929135	46	53	quality	T080	C0332306
27929135	54	60	memory	T025	C0682639
27929135	61	73	CD8+ T cells	T025	C0242629
27929135	77	83	infant	T008	C0920362
27929135	84	88	mice	T015	C0025929
27929135	95	110	non-replicating	T045	C1511692
27929135	111	129	adenoviral vectors	T114	C1510800
27929135	130	143	Intracellular	T082	C0178719
27929135	144	153	pathogens	T001	C0450254
27929135	166	173	serious	T080	C0205404
27929135	174	180	threat	T078	C0749385
27929135	188	193	early	T079	C1279919
27929135	194	198	life	T078	C0376558
27929135	229	242	immune system	T022	C0020962
27929135	246	254	newborns	T100	C0021289
27929135	279	294	developmentally	T039	C0243107
27929135	295	303	immature	T080	C0205252
27929135	312	322	propensity	T081	C2718044
27929135	334	337	Th2	T025	C0242633
27929135	338	346	immunity	T039	C0020964
27929135	348	359	significant	T078	C0750502
27929135	360	371	CD8+ T-cell	T025	C0242629
27929135	372	381	responses	T043	C1318468
27929135	395	403	elicited	T080	C0449265
27929135	422	429	optimal	T080	C2698651
27929135	430	437	priming	T169	C0871133
27929135	439	460	Replication deficient	T045	C1511692
27929135	461	479	adenoviral vectors	T114	C1510800
27929135	506	512	induce	T169	C0205263
27929135	520	531	CD8+ T-cell	T025	C0242629
27929135	532	540	response	T043	C1318468
27929135	544	548	mice	T015	C0026809
27929135	550	558	primates	T015	C0033147
27929135	563	569	humans	T016	C0086418
27929135	632	653	replication-deficient	T045	C1511692
27929135	654	666	adenovectors	T114	C1510800
27929135	673	681	overcome	T052	C2983310
27929135	686	690	risk	T078	C0035647
27929135	694	706	overwhelming	T081	C1704243
27929135	707	726	antigen stimulation	T039	C2250751
27929135	738	750	first period	T079	C0580206
27929135	754	758	life	T078	C0376558
27929135	773	782	pertinent	T080	C2347946
27929135	783	794	alternative	T077	C1523987
27929135	798	804	infant	T100	C0021270
27929135	805	816	vaccinology	T061	C0042196
27929135	835	841	infant	T008	C0920362
27929135	842	846	mice	T015	C0025929
27929135	852	862	vaccinated	T033	C1519885
27929135	884	902	adenoviral vectors	T114	C1510800
27929135	911	922	CD8+ T-cell	T025	C0242629
27929135	923	931	response	T043	C1318468
27929135	938	943	early	T079	C1279919
27929135	944	948	life	T078	C0376558
27929135	949	960	vaccination	T061	C0042196
27929135	991	1000	frequency	T079	C0439603
27929135	1002	1019	polyfunctionality	T169	C0205245
27929135	1032	1044	cytotoxicity	T049	C0596402
27929135	1052	1060	elicited	T080	C0449265
27929135	1061	1067	memory	T025	C0682639
27929135	1068	1080	CD8+ T cells	T025	C0242629
27929135	1097	1106	potential	T080	C3245505
27929135	1116	1121	cells	T025	C0242629
27929135	1125	1132	respond	T032	C0871261
27929135	1136	1156	secondary infections	T047	C0442886
27929135	1168	1178	protection	T061	C0150259
27929135	1191	1197	tested	T169	C0039593
27929135	1202	1208	impact	T080	C4049986
27929135	1212	1220	maternal	T033	C1858460
27929135	1221	1229	immunity	T039	C0020964
27929135	1230	1237	against	T080	C0521124
27929135	1242	1263	replication-deficient	T045	C1511692
27929135	1264	1281	adenoviral vector	T114	C1510800
27929135	1289	1294	early	T079	C1279919
27929135	1295	1299	life	T078	C0376558
27929135	1300	1311	vaccination	T061	C0042196
27929135	1313	1320	Overall	T080	C1561607
27929135	1348	1354	memory	T025	C0682639
27929135	1355	1367	CD8+ T cells	T025	C0242629
27929135	1368	1375	induced	T169	C0205263
27929135	1379	1397	adenoviral vectors	T114	C1510800
27929135	1401	1407	infant	T008	C0920362
27929135	1408	1412	mice	T015	C0025929
27929135	1425	1432	quality	T080	C0332306
27929135	1437	1442	match	T080	C1708943
27929135	1449	1457	elicited	T080	C0449265
27929135	1465	1470	adult	T008	C0596888
27929135	1471	1475	host	T001	C1167395